Friday, 16 October 2026European Markets

MicroPower Stock Soars 20%+: Investors Rejoice

Loading stream...

(VIANEWS) -

About ENSURGE MICROPOWER

Ensurge Micropower ASA, previously known as Thin Film Electronics ASA, specializes in producing and selling ultrathin energy storage solutions using solid-state lithium battery technology for wearable devices, connected sensors and other applications. Established in 2005 in Oslo, Norway.

Yearly Analysis

ENSURGE MICROPOWER's stock is currently trading at kr0.35, significantly below its 52-week high of 4.19 and higher than its 52-week low of 0.10. This indicates a considerable decrease in value over the last year. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization and is currently at -150.46 for this company. A negative EBITDA indicates that operations are currently operating at a loss without producing any profits and could be cause for concern among investors as it indicates it may not be financially secure in the short term. Investors should proceed with caution when investing in ENSURGE MICROPOWER's stock given its current low valuation and negative EBITDA. Prior to making any definitive investment decisions, further research should be performed and analysis performed before taking any definitive steps.

Technical Analysis

ENSURGE MICROPOWER's stock price has seen significant fluctuations recently, currently trading at around kr0.10; significantly below its 50-day moving average of kr0.12 and far beneath its 200-day moving average of kr0.76. Nevertheless, investors remain bullish on ENSURGE MICROPOWER as today's last reported volume is 226277483 which represents 284.68% more volume than its usual volume of 58821300. ENSURGE MICROPOWER has experienced high levels of stock price volatility. Over the last week, month and quarter, intraday variation averages were 14.16%, 7.08% and 6.51%, with its highest amplitude being 24.69% (last week), 12.97% (month) and 6.51% (quarter). According to the stochastic oscillator, which provides an effective indicator for overbought and oversold conditions, ENSURGE MICROPOWER's stock appears overbought (>=80). This suggests it could be in need of short-term correction. However, past performance does not guarantee future outcomes and investors should carefully consider their risk tolerance and investment objectives before making any definitive investment decisions.

Equity Analysis

Earnings per share (EPS) is a financial metric used to measure how much profit a company generates per outstanding share. A negative EPS, like that seen for ENSURGE MICROPOWER's trailing twelve months EPS of kr-0.5 indicates that they have suffered losses and do not generate profits for shareholders; such information provides invaluable insights into financial health and performance of a business.

More news about ENSURGE MICROPOWER (ENSU.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com